Sunday, September 30, 2018

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.

from Moneycontrol Business News https://ift.tt/2Iutlyu
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bitcoin stays near $64K, Ethereum underperforms as weak risk appetite keeps crypto markets under pressure

Bitcoin traded near $64,000 and Ethereum underperformed as risk appetite weakened. The global crypto market capitalization edged down 2% to ...